Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed about notice issued for the attention of equity shareholders of the company on 15.11.2017 which was published on 18.11.2017, intimating that the equity shares in respect of which dividend remain unclaimed for seven consecutive years, would be transferred to Investor Education and Protection Fund (IEPF), in Business Standard (English newspaper) and Andhra Prabha (Telugu newspaper).
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: